Fly Intel: Pre-market Movers

HIGHER: Akcea Therapeutics (AKCA), up 16% after announcing topline results from the Phase 2 study of AKCEA-APOCIII-LRx in the treatment of patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease. The study met the primary endpoint of significant triglyceride lowering and multiple secondary endpoints with a favorable safety and tolerability profile... Tesla (TSLA), up 4% after Wedbush analyst Daniel Ives said he believes the stock will not disappoint Tesla bulls next week when the company reports earnings and gives guidance, noting that underlying strength in demand in China and Europe look robust based on his analysis. The analyst, who thinks Tesla's delivery guidance is likely to be strong and believes the China opportunity is worth "at least $100 per share," or $300 in a bull case scenario, raised his price target on Tesla shares to $550 from $370 ahead of earnings. Ives, whose new long term bull case scenario on the stock is $900, maintains a Neutral rating on Tesla shares. UP AFTER EARNINGS: Abbott (ABT), up 1%... Ally Financial (ALLY), up 3%... IBM (IBM), up 3%. DOWN AFTER EARNINGS: Baker Hughes (BKR), down 1%... FuelCell (FCEL), down 20%... Zions Bancorp (ZION), down 4%. LOWER: Arconic (ARNC), down 1% after Longbow analyst Chris Olin says he believes shares could lose up to $400M of previously expected commercial aerospace revenue in CY20. In a research note to investors, Olin, who made no change to his Neutral rating, says recent communications between Boeing (BA) and its main global suppliers suggests the OEM is likely to issue conservative 737 production targets for CY20, starting at 21/month followed by a shift to 28/month... Ellington Financial (EFC), down 2% after 4.6M share Spot Secondary priced at $18.29.